Urothelial Bladder Tumours

Overview

Bladder tumours: epithelial (majority) vs non-epithelial (uncommon). >90% UROTHELIAL (transitional cell), continuous with renal pelvis/ureters/urethra epithelium. ~3% of all cancers, >5th decade, 3x male preponderance.

Etiopathogenesis

MULTIFOCAL, “field effect” → multicentricity + recurrence at new sites over time (POLYCHRONOTROPISM).

1. Smoking — 2-4x risk (↑urinary carcinogen excretion)
2. Industrial occupation — aniline dyes, rubber, plastic, textile, cable; ~20yr exposure; β-naphthylamine+benzene metabolites
3. Schistosomiasis (S. haematobium) — ↑SQUAMOUS CELL carcinoma risk specifically; Egypt/Sudan endemic
4. Dietary — tryptophan metabolites (experimental); saccharin/caffeine/alcohol controversial
5. Local lesions — extrophied bladder, diverticulum, leukoplakia, diverted bladder (all via squamous metaplasia)
6. Drugs — cyclophosphamide, phenacetin abuse
7. Prior pelvic irradiation

Genetics: FGFR3, p53, RB, p21 mutations → higher recurrence/metastasis.

Morphology

Gross: single/multiple. ~90% PAPILLARY, ~10% flat indurated. Sites: lateral walls > posterior wall > trigone.

WHO/ISUP classification (continuous spectrum, not discrete categories)

• Papilloma — exophytic (small, delicate, normal cells, ≤6-7 layers, no mitoses; can recur) or inverted (endophytic, benign)
• CIS — anaplastic cells confined superficial to BM; cytology = high-grade despite flat/non-invasive. PROGRESSES 50-75% UNTREATED — critical point, “in situ” is misleadingly reassuring here
• PUNLMP — papilloma-like + more layers + diffuse nuclear enlargement; no invasion, can recur
• Low-grade papillary carcinoma — orderly, cohesive, mild variation, infrequent mitoses (lower half only)
• High-grade papillary carcinoma — disorderly, thick, marked pleomorphism/hyperchromatism, multiple nucleoli, frequent atypical mitoses any level
• Invasive — any grade can invade lamina propria/muscularis propria; ± squamous/glandular metaplasia foci

Other variants

• Squamous cell carcinoma (~5%) — unlike TCC’s papillary/non-ulcerating pattern, mostly SESSILE/nodular/infiltrating/ulcerating. Schistosomiasis link. Well-diff (keratin pearls) to anaplastic.
• Adenocarcinoma (rare) — exstrophy/glandular metaplasia, urachal remnants, periurethral/periprostatic glands, cystitis cystica. Glandular/tubular ± mucin.
• Small cell carcinoma (rare) — resembles pulmonary neuroendocrine carcinoma, WORSE prognosis.
• Mixed carcinoma — combined types.

Staging

Stage 0 (mucosa) → A (lamina propria) → B1 (superficial muscle) → B2 (deep muscle) → C (perivesical tissue) → D1 (regional mets) → D2 (distant mets).

Non-epithelial tumours (uncommon)

Benign: leiomyoma (commonest), neurofibroma, haemangioma, granular cell myoblastoma. Malignant: RHABDOMYOSARCOMA commonest — adult form (>40yr, resembles skeletal muscle) vs childhood form (SARCOMA BOTRYOIDES/embryonal — polypoid “grape-like” mass, pleomorphic stellate cells in myxomatous background; similar tumour in female genital tract).

Related: renal pelvis/ureter/urethral tumours

Renal pelvis/ureter tumours: nearly all epithelial, same types as bladder (ureteral tumours rare). Urethral tumours rare — urethral caruncle = notable exception (inflammatory tumour-LIKE lesion, not true neoplasm).

Clinical relevance

WHO/ISUP spectrum = ONE continuous biological gradient (architectural+cytologic disorder), not discrete categories — each grade step = progressively greater loss of normal orderly/polarised/cohesive architecture. CIS’s high progression rate (50-75% untreated) despite “non-invasive” label = critical distinction from CIS elsewhere — bladder CIS is high-grade disease by cytology, must be treated aggressively not observed. Field-effect/polychronotropism = why surveillance continues indefinitely after apparent treatment success — entire urothelium shares same carcinogenic field exposure, new tumours ≠ treatment failure. Squamous cell carcinoma’s schistosomiasis link = geographically concentrated high-yield fact — endemic regions (Egypt/Sudan) shift histologic profile substantially toward squamous, genuinely different epidemiology from elsewhere.

Overview

Bladder tumours are epithelial (vast majority) or non-epithelial (uncommon). >90% are urothelial (transitional cell) tumours, arising from the transitional epithelium continuous with the renal pelvis, ureters, and most of the urethra. Bladder cancer is ~3% of all cancers, mostly beyond the 5th decade, 3× male preponderance.

Etiopathogenesis

Urothelial tumours are typically multifocal, with disease patterns emerging over years — a “field effect” across the urothelium explains both the multicentricity and the tendency to recur at new sites over time (polychronotropism).

1. Smoking — 2–4× risk, via increased urinary excretion of carcinogens.
2. Industrial occupation — aniline dye, rubber, plastic, textile, cable workers; risk after ~20 years exposure; causative agents are β-naphthylamine and benzene metabolites.
3. Schistosomiasis (S. haematobium) — raises risk specifically of squamous cell carcinoma; common in Egypt/Sudan, explaining high regional bladder cancer rates; mechanism: chronic local irritation → squamous metaplasia → squamous cell carcinoma.
4. Dietary factors — carcinogenic tryptophan metabolites (experimental evidence); saccharin/caffeine/alcohol roles remain controversial.
5. Local lesions — extrophied bladder, vesical diverticulum, leukoplakia, defunctionalised/diverted bladder — all via squamous metaplasia.
6. Drugs — cyclophosphamide, analgesic (phenacetin) abuse nephropathy.
7. Prior pelvic irradiation.

Genetics: mutations in FGFR3, p53, RB, p21 — associated with higher recurrence/metastasis rates.

Morphology

Gross: single or multiple; ~90% papillary (non-invasive or invasive), ~10% flat indurated. Commonest sites: lateral walls, then posterior wall, trigone. Papillary tumours are free-floating, fern-like, on a broad or narrow pedicle; non-papillary tumours are bulkier, ulcerated.

WHO/ISUP Classification (Histologic Categories)

A graded spectrum from benign to high-grade malignant, distinguished by architecture, cytology, and invasion:

• Urothelial papilloma — exophytic (small, delicate papillae, normal-appearing cells, ≤6–7 layers, no mitoses, retained polarity; can recur) or inverted (endophytic, benign).
• Carcinoma in situ (CIS) — anaplastic malignant cells confined superficial to the basement membrane; cytologically resembles high-grade carcinoma (loss of cohesion, pleomorphism, mitoses) despite being flat and non-invasive. Progresses to invasive cancer in 50–75% if untreated — a critical management point.
• PUNLMP (papillary urothelial neoplasm of low malignant potential) — papilloma-like but with more epithelial layers and diffuse nuclear enlargement; no invasion, but can recur.
• Papillary urothelial carcinoma, low grade — orderly, cohesive, mild nuclear/chromatin variation, infrequent mitoses confined to the lower half.
• Papillary urothelial carcinoma, high grade — disorderly, thickened, marked nuclear pleomorphism/hyperchromatism, multiple prominent nucleoli, frequent atypical mitoses at any level.
• Invasive urothelial carcinoma — any grade may invade lamina propria or muscularis propria (detrusor); squamous/glandular metaplastic foci can occur in any grade.

Other Histologic Variants

• Squamous cell carcinoma (~5%) — unlike TCC’s typically papillary, non-ulcerating pattern, most are sessile, nodular, infiltrating, ulcerating; linked to schistosomiasis; ranges well-differentiated (keratin pearls) to anaplastic.
• Adenocarcinoma (rare) — associated with bladder exstrophy/glandular metaplasia, urachal remnants, periurethral/periprostatic glands, or cystitis cystica; glandular/tubular pattern ± mucin.
• Small cell carcinoma (rare) — resembles pulmonary/other neuroendocrine small cell carcinoma; worse prognosis.
• Mixed carcinoma — combination of histologic types.

Staging

A simple, clinically useful staging scheme:

• Stage 0 — confined to mucosa.
• Stage A — invades lamina propria, not muscularis.
• Stage B1 — invades superficial muscle.
• Stage B2 — invades deep muscle.
• Stage C — invades perivesical tissue.
• Stage D1 — regional metastases.
• Stage D2 — distant metastases.

Non-Epithelial Bladder Tumours (Uncommon)

• Benign: leiomyoma (commonest), neurofibroma, haemangioma, granular cell myoblastoma.
• Malignant: rhabdomyosarcoma is the most frequent — adult form (>40 years, resembles skeletal muscle rhabdomyosarcoma) versus childhood form (sarcoma botryoides/embryonal rhabdomyosarcoma — large, polypoid, soft, “grape-like” mass; pleomorphic stellate embryonic mesenchymal cells in a myxomatous background; a similar tumour occurs in the female genital tract).

Related: Renal Pelvis, Ureter, and Urethral Tumours

Nearly all renal pelvis/ureteral tumours are epithelial, of the same types as bladder tumours (ureteral tumours are rare). Urethral tumours are rare, with the urethral caruncle (an inflammatory tumour-like lesion, not a true neoplasm) being the notable exception.

Clinical Relevance

• The WHO/ISUP grading spectrum (papilloma → PUNLMP → low-grade → high-grade urothelial carcinoma) is best understood as a single continuous biological gradient of architectural and cytologic disorder, not discrete unrelated categories — each step up the grade reflects progressively greater loss of the normal orderly, polarised, cohesive urothelial architecture.
• Carcinoma in situ’s high progression rate (50–75% untreated) despite being flat and technically “non-invasive” is a critical point that separates CIS from the reassuring connotation “in situ” often carries in other organs — in the bladder, CIS is high-grade disease by cytology and must be treated aggressively, not observed.
• The field-effect/polychronotropism concept explains why bladder cancer surveillance continues indefinitely after apparent treatment success — the entire urothelium (renal pelvis to urethra) carries the same field-level carcinogenic exposure, so new tumours arising at different times and different sites reflect the same underlying process, not a failure of the original treatment.
• Squamous cell carcinoma’s schistosomiasis association is a geographically concentrated but high-yield fact — in endemic regions (Egypt, Sudan), bladder cancer’s histologic profile shifts substantially toward squamous carcinoma, a genuinely different epidemiologic pattern from the urothelial-carcinoma-dominant picture seen elsewhere.

• WHO/ISUP grading spectrum from papilloma to high-grade carcinoma as one continuous gradient
• Bladder cancer staging (0 through D2) mapped to depth of invasion

Multiple Choice Questions (1)